AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Agilon Health CEO resigns, suspends FY22 guidance.
ByAinvest
Saturday, Sep 13, 2025 10:10 am ET1min read
• Pomerantz LLP investigates agilon health for securities fraud allegations • Investigation concerns whether agilon and its officers/directors engaged in unlawful practices • agilon's CEO and President, Steven Sell, resigned on August 4, 2025 • agilon suspended its full-year 2025 financial guidance due to market uncertainty • Investors advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980 to join the class action.
New York, September 12, 2025 - Pomerantz LLP, a renowned law firm specializing in corporate, securities, and antitrust class litigation, has announced an investigation into allegations of securities fraud against Agilon Health, Inc. (NYSE: AGL). The investigation, led by Danielle Peyton, aims to determine whether Agilon and its officers or directors engaged in unlawful practices.The investigation follows the resignation of Agilon's CEO and President, Steven Sell, on August 4, 2025. Sell's departure was accompanied by Agilon's decision to suspend its previously issued full-year 2025 financial guidance, citing market uncertainty and ongoing initiatives. The stock price of Agilon subsequently fell by $0.93 per share, or 51.51%, to close at $0.88 per share on August 5, 2025 [1].
Investors affected by these events are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, to join a potential class action. Pomerantz LLP is known for its expertise in securities class actions and has a history of recovering multimillion-dollar damages on behalf of its clients [1].
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet